Cargando…

COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

SIMPLE SUMMARY: There are contradictory data about coronavirus disease (COVID-19) in patients with hematological malignancies. In this population-based study we evaluated severity and survival of unvaccinated patients with hematological malignancies (HM) and COVID-19 in the Madrid region, Spain, bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-López, Joaquín, De la Cruz, Javier, Gil-Manso, Rodrigo, Alegre, Adrián, Ortiz, Javier, Llamas, Pilar, Martínez, Yolanda, Hernández-Rivas, José-Ángel, González-Gascón, Isabel, Benavente, Celina, Estival Monteliu, Pablo, Jiménez-Yuste, Víctor, Canales, Miguel, Bastos, Mariana, Kwon, Mi, Valenciano, Susana, Callejas-Charavia, Marta, López-Jiménez, Javier, Herrera, Pilar, Duarte, Rafael, Núñez Martín-Buitrago, Lucía, Sanchez Godoy, Pedro, Jacome Yerovi, Cristina, Martínez-Barranco, Pilar, García Roa, María, Escolano Escobar, Cristian, Matilla, Arturo, Rosado Sierra, Belén, Aláez-Usón, María Concepción, Quiroz-Cervantes, Keina, Martínez-Chamorro, Carmen, Pérez-Oteyza, Jaime, Martos-Martinez, Rafael, Herráez, Regina, González-Santillana, Clara, Del Campo, Juan Francisco, Alonso, Arancha, de la Fuente, Adolfo, Pascual, Adriana, Bustelos-Rodriguez, Rosalía, Sebrango, Ana, Ruiz, Elena, Marcheco-Pupo, Eriel Alexis, Grande, Carlos, Cedillo, Ángel, Lumbreras, Carlos, Arroyo Barea, Andrés, Casas-Rojo, José Manuel, Calbacho, Maria, Diez-Martín, José Luis, García-Suárez, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001264/
https://www.ncbi.nlm.nih.gov/pubmed/36900296
http://dx.doi.org/10.3390/cancers15051497
_version_ 1784904092416475136
author Martínez-López, Joaquín
De la Cruz, Javier
Gil-Manso, Rodrigo
Alegre, Adrián
Ortiz, Javier
Llamas, Pilar
Martínez, Yolanda
Hernández-Rivas, José-Ángel
González-Gascón, Isabel
Benavente, Celina
Estival Monteliu, Pablo
Jiménez-Yuste, Víctor
Canales, Miguel
Bastos, Mariana
Kwon, Mi
Valenciano, Susana
Callejas-Charavia, Marta
López-Jiménez, Javier
Herrera, Pilar
Duarte, Rafael
Núñez Martín-Buitrago, Lucía
Sanchez Godoy, Pedro
Jacome Yerovi, Cristina
Martínez-Barranco, Pilar
García Roa, María
Escolano Escobar, Cristian
Matilla, Arturo
Rosado Sierra, Belén
Aláez-Usón, María Concepción
Quiroz-Cervantes, Keina
Martínez-Chamorro, Carmen
Pérez-Oteyza, Jaime
Martos-Martinez, Rafael
Herráez, Regina
González-Santillana, Clara
Del Campo, Juan Francisco
Alonso, Arancha
de la Fuente, Adolfo
Pascual, Adriana
Bustelos-Rodriguez, Rosalía
Sebrango, Ana
Ruiz, Elena
Marcheco-Pupo, Eriel Alexis
Grande, Carlos
Cedillo, Ángel
Lumbreras, Carlos
Arroyo Barea, Andrés
Casas-Rojo, José Manuel
Calbacho, Maria
Diez-Martín, José Luis
García-Suárez, Julio
author_facet Martínez-López, Joaquín
De la Cruz, Javier
Gil-Manso, Rodrigo
Alegre, Adrián
Ortiz, Javier
Llamas, Pilar
Martínez, Yolanda
Hernández-Rivas, José-Ángel
González-Gascón, Isabel
Benavente, Celina
Estival Monteliu, Pablo
Jiménez-Yuste, Víctor
Canales, Miguel
Bastos, Mariana
Kwon, Mi
Valenciano, Susana
Callejas-Charavia, Marta
López-Jiménez, Javier
Herrera, Pilar
Duarte, Rafael
Núñez Martín-Buitrago, Lucía
Sanchez Godoy, Pedro
Jacome Yerovi, Cristina
Martínez-Barranco, Pilar
García Roa, María
Escolano Escobar, Cristian
Matilla, Arturo
Rosado Sierra, Belén
Aláez-Usón, María Concepción
Quiroz-Cervantes, Keina
Martínez-Chamorro, Carmen
Pérez-Oteyza, Jaime
Martos-Martinez, Rafael
Herráez, Regina
González-Santillana, Clara
Del Campo, Juan Francisco
Alonso, Arancha
de la Fuente, Adolfo
Pascual, Adriana
Bustelos-Rodriguez, Rosalía
Sebrango, Ana
Ruiz, Elena
Marcheco-Pupo, Eriel Alexis
Grande, Carlos
Cedillo, Ángel
Lumbreras, Carlos
Arroyo Barea, Andrés
Casas-Rojo, José Manuel
Calbacho, Maria
Diez-Martín, José Luis
García-Suárez, Julio
author_sort Martínez-López, Joaquín
collection PubMed
description SIMPLE SUMMARY: There are contradictory data about coronavirus disease (COVID-19) in patients with hematological malignancies. In this population-based study we evaluated severity and survival of unvaccinated patients with hematological malignancies (HM) and COVID-19 in the Madrid region, Spain, between early February 2020 and February 2021. Also, a comparison was made with non-cancer patients from the SEMI-COVID registry and post COVID-19 conditions were evaluated. Overall, 30-day mortality was 32.7%, with higher mortality among certain groups of patients (aged ≥ 60 years, presence of ≥ 3 comorbidities, diagnosis of AML/ALL, treatment with conventional chemotherapy within 30 days of COVID-19 diagnosis, recipients of systemic corticosteroids as COVID-19 therapy). Mortality rates were similar between earlier and later phases of the pandemic, not paralleling the reduction of mortality in non-cancer patients. Up to 27.3% patients had a post COVID-19 condition. These findings will be useful to understand COVID-19 morbidity and mortality in unvaccinated patients diagnosed with HM. ABSTRACT: Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis.
format Online
Article
Text
id pubmed-10001264
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100012642023-03-11 COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study Martínez-López, Joaquín De la Cruz, Javier Gil-Manso, Rodrigo Alegre, Adrián Ortiz, Javier Llamas, Pilar Martínez, Yolanda Hernández-Rivas, José-Ángel González-Gascón, Isabel Benavente, Celina Estival Monteliu, Pablo Jiménez-Yuste, Víctor Canales, Miguel Bastos, Mariana Kwon, Mi Valenciano, Susana Callejas-Charavia, Marta López-Jiménez, Javier Herrera, Pilar Duarte, Rafael Núñez Martín-Buitrago, Lucía Sanchez Godoy, Pedro Jacome Yerovi, Cristina Martínez-Barranco, Pilar García Roa, María Escolano Escobar, Cristian Matilla, Arturo Rosado Sierra, Belén Aláez-Usón, María Concepción Quiroz-Cervantes, Keina Martínez-Chamorro, Carmen Pérez-Oteyza, Jaime Martos-Martinez, Rafael Herráez, Regina González-Santillana, Clara Del Campo, Juan Francisco Alonso, Arancha de la Fuente, Adolfo Pascual, Adriana Bustelos-Rodriguez, Rosalía Sebrango, Ana Ruiz, Elena Marcheco-Pupo, Eriel Alexis Grande, Carlos Cedillo, Ángel Lumbreras, Carlos Arroyo Barea, Andrés Casas-Rojo, José Manuel Calbacho, Maria Diez-Martín, José Luis García-Suárez, Julio Cancers (Basel) Article SIMPLE SUMMARY: There are contradictory data about coronavirus disease (COVID-19) in patients with hematological malignancies. In this population-based study we evaluated severity and survival of unvaccinated patients with hematological malignancies (HM) and COVID-19 in the Madrid region, Spain, between early February 2020 and February 2021. Also, a comparison was made with non-cancer patients from the SEMI-COVID registry and post COVID-19 conditions were evaluated. Overall, 30-day mortality was 32.7%, with higher mortality among certain groups of patients (aged ≥ 60 years, presence of ≥ 3 comorbidities, diagnosis of AML/ALL, treatment with conventional chemotherapy within 30 days of COVID-19 diagnosis, recipients of systemic corticosteroids as COVID-19 therapy). Mortality rates were similar between earlier and later phases of the pandemic, not paralleling the reduction of mortality in non-cancer patients. Up to 27.3% patients had a post COVID-19 condition. These findings will be useful to understand COVID-19 morbidity and mortality in unvaccinated patients diagnosed with HM. ABSTRACT: Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis. MDPI 2023-02-27 /pmc/articles/PMC10001264/ /pubmed/36900296 http://dx.doi.org/10.3390/cancers15051497 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martínez-López, Joaquín
De la Cruz, Javier
Gil-Manso, Rodrigo
Alegre, Adrián
Ortiz, Javier
Llamas, Pilar
Martínez, Yolanda
Hernández-Rivas, José-Ángel
González-Gascón, Isabel
Benavente, Celina
Estival Monteliu, Pablo
Jiménez-Yuste, Víctor
Canales, Miguel
Bastos, Mariana
Kwon, Mi
Valenciano, Susana
Callejas-Charavia, Marta
López-Jiménez, Javier
Herrera, Pilar
Duarte, Rafael
Núñez Martín-Buitrago, Lucía
Sanchez Godoy, Pedro
Jacome Yerovi, Cristina
Martínez-Barranco, Pilar
García Roa, María
Escolano Escobar, Cristian
Matilla, Arturo
Rosado Sierra, Belén
Aláez-Usón, María Concepción
Quiroz-Cervantes, Keina
Martínez-Chamorro, Carmen
Pérez-Oteyza, Jaime
Martos-Martinez, Rafael
Herráez, Regina
González-Santillana, Clara
Del Campo, Juan Francisco
Alonso, Arancha
de la Fuente, Adolfo
Pascual, Adriana
Bustelos-Rodriguez, Rosalía
Sebrango, Ana
Ruiz, Elena
Marcheco-Pupo, Eriel Alexis
Grande, Carlos
Cedillo, Ángel
Lumbreras, Carlos
Arroyo Barea, Andrés
Casas-Rojo, José Manuel
Calbacho, Maria
Diez-Martín, José Luis
García-Suárez, Julio
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
title COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
title_full COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
title_fullStr COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
title_full_unstemmed COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
title_short COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
title_sort covid-19 severity and survival over time in patients with hematologic malignancies: a population-based registry study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001264/
https://www.ncbi.nlm.nih.gov/pubmed/36900296
http://dx.doi.org/10.3390/cancers15051497
work_keys_str_mv AT martinezlopezjoaquin covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT delacruzjavier covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT gilmansorodrigo covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT alegreadrian covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT ortizjavier covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT llamaspilar covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT martinezyolanda covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT hernandezrivasjoseangel covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT gonzalezgasconisabel covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT benaventecelina covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT estivalmonteliupablo covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT jimenezyustevictor covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT canalesmiguel covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT bastosmariana covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT kwonmi covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT valencianosusana covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT callejascharaviamarta covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT lopezjimenezjavier covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT herrerapilar covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT duarterafael covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT nunezmartinbuitragolucia covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT sanchezgodoypedro covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT jacomeyerovicristina covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT martinezbarrancopilar covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT garciaroamaria covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT escolanoescobarcristian covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT matillaarturo covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT rosadosierrabelen covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT alaezusonmariaconcepcion covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT quirozcervanteskeina covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT martinezchamorrocarmen covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT perezoteyzajaime covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT martosmartinezrafael covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT herraezregina covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT gonzalezsantillanaclara covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT delcampojuanfrancisco covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT alonsoarancha covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT delafuenteadolfo covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT pascualadriana covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT bustelosrodriguezrosalia covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT sebrangoana covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT ruizelena covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT marchecopupoerielalexis covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT grandecarlos covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT cedilloangel covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT lumbrerascarlos covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT arroyobareaandres covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT casasrojojosemanuel covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT calbachomaria covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT diezmartinjoseluis covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy
AT garciasuarezjulio covid19severityandsurvivalovertimeinpatientswithhematologicmalignanciesapopulationbasedregistrystudy